Executive Summary
Lung cancer (non-small cell lung cancer, NSCLC, and small cell lung cancer, SCLC) features numerous laboratory-detectable biomarkers that provide critical information for diagnosis (Dx), prognosis (Px), and prediction (Prd) of therapeutic response. This comprehensive clinical decision support system presents the main laboratory biomarkers, integrating evidence from the last 5-10 years.
Each biomarker is systematically rated using the IECC ONE-ME® system, supported by high-impact references with detailed evidence levels, impact factors, and citation metrics. This tool assists healthcare professionals in making informed decisions regarding biomarker selection and interpretation in lung cancer management.
Search & Filter
IECC ONE-ME® Scoring System
Diagnostic Value (Dx)
Ability to detect or confirm cancer presence
Prognostic Value (Px)
Ability to predict disease outcome
Predictive Value (Prd)
Ability to predict treatment response
Laboratory Biomarkers
IECC Complete Database Table
| Disease ID | Biomarker Name | SNOMED CT | ICD-10 | RadLex | LOINC | Clinical Role | Evidence Level | Dx Score | Px Score | Prd Score | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | AUC | Cutoff Value | Units | Reference Range | Sample Type | Methodology | Cancer Type | Population | Version Tag | Effective Date | Status | Created By | Modified By | Quality Score | Confidence Level | Study Population | Primary Reference | Impact Factor | Citation Count | Clinical Guidelines |
|---|
Performance Analysis Charts
IECC Scores Comparison
Sensitivity vs Specificity
Evidence Quality Distribution
Clinical Applications
Bibliography & Evidence Base
📊 Bibliographic Quantification System
Impact Factor (IF)
Measures journal influence and importance in scientific field
Citation Count
Indicates study relevance and influence in scientific community
Evidence Levels
Hierarchical classification of methodological quality
Key References
Glossary & Acronyms
Biomarker Acronyms
Oncofetal protein used as tumor marker
Soluble fragment of cytokeratin-19
Glycolytic enzyme in neuroendocrine cells
Precursor of gastrin-releasing peptide
Glycoprotein tumor marker
Glycoprotein associated with squamous cancers
Clinical Terms
~85% of lung cancers
~15% of lung cancers
Probability of disease given positive test
Probability of no disease given negative test
Measure of diagnostic accuracy
Relative risk of event occurrence